Idorsia pairs with Neurocrine in potential $400 mln epilepsy drug deal
January 10, 2020 at 02:40 AM EST
Swiss biotech group Idorsia on Friday lifted the lid off a 2019 deal for its investigational epilepsy medicine, revealing the pact that is potentially worth more than $400 million is with U.S.-based Neurocrine Biosciences.
